NEWELL WILLIAM J 4

4 · SUTRO BIOPHARMA, INC. · Filed Mar 7, 2024

Form 4

Period: 2024-03-05

DirectorCEO

Transactions

Award
Stock Option (Right to Buy Common Stock)
2024-03-05+174,000→ 174,000 total
Exercise: $4.54Exp: 2034-03-05→ Common Stock (174,000 underlying)
Award
Restricted Stock Units (RSUs)
2024-03-05+130,500→ 130,500 total
Exp: 2028-03-01→ Common Stock (130,500 underlying)
Exercise/Conversion
Common Stock
2024-03-05+18,750→ 226,893 total
Tax Payment
Common Stock
2024-03-05$4.54/sh−6,690$30,373→ 220,203 total
Exercise/Conversion
Restricted Stock Unit (RSU)
2024-03-05−18,750→ 18,750 total
Exp: 2025-03-05→ Common Stock (18,750 underlying)

Holdings

Footnotes (6)

[F1]Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
[F2]The securities are held of record by the reporting person as trustee of the William J. Newell Family Trust DTD 03/15/2019.
[F3]The option vests as to 2.0833% of the total award monthly, beginning on April 1, 2024, with 100% of the award being vested and exercisable on March 1, 2028, subject to the reporting person's continued service to the Issuer on each vesting date.
[F4]Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
[F5]The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date.
[F6]The RSUs vest as to 1/4th of the total award annually beginning on March 5, 2022, subject to continued service through each vesting date.

Documents

1 file